These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 17092678)
1. [Antibiotherapy for acute CAP in adults]. Denes E Med Mal Infect; 2006; 36(11-12):718-33. PubMed ID: 17092678 [TBL] [Abstract][Full Text] [Related]
2. [Acute community-acquired pneumonia. A review of clinical trials]. Chidiac C Med Mal Infect; 2006; 36(11-12):650-66. PubMed ID: 16876363 [TBL] [Abstract][Full Text] [Related]
3. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924 [TBL] [Abstract][Full Text] [Related]
4. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Grossman RF; Rotschafer JC; Tan JS Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675 [TBL] [Abstract][Full Text] [Related]
5. Community-acquired pneumonia in adults. Sue DY West J Med; 1994 Oct; 161(4):383-9. PubMed ID: 7817549 [TBL] [Abstract][Full Text] [Related]
6. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Segreti J; House HR; Siegel RE Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674 [TBL] [Abstract][Full Text] [Related]
8. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents. Roig J; Casal J; Gispert P; Gea E Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177 [TBL] [Abstract][Full Text] [Related]
9. Role of gemifloxacin in community-acquired pneumonia. Tillotson GS Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107 [TBL] [Abstract][Full Text] [Related]
10. [Reducing the duration of antibiotic therapy in acute community-acquired pneumonia]. Groupe Entretiens du Club de réflexion sur l'infection respiratoire Rev Pneumol Clin; 2008 Feb; 64(1):3-7. PubMed ID: 18603172 [TBL] [Abstract][Full Text] [Related]
11. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines. Simoens S Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults]. Trémolières F; Mayaud C; Mouton Y; Weber P; Dellatolas F; Caulin E Pathol Biol (Paris); 2005; 53(8-9):503-10. PubMed ID: 16181747 [TBL] [Abstract][Full Text] [Related]
13. [Evaluation of clinical practice, medical computerized database and improvement of antibiotic therapy for acute community-acquired pneumonia]. Roger PM; De Salvador F; Schiano MH; Cua E; Rancurel S; Farhad R; Pulcini C; Bernard E Med Mal Infect; 2010 Jul; 40(7):412-7. PubMed ID: 20116948 [TBL] [Abstract][Full Text] [Related]
14. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. Cantón R; Lode H; Graninger W; Milkovich G Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873 [TBL] [Abstract][Full Text] [Related]
15. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. Bartlett JG Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295 [TBL] [Abstract][Full Text] [Related]